MedTrace Logo

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

NCT01193101 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 389

Last updated 2016-02-15

Study results available
· View outcomes & findings →

Summary

This study is a phase 2 study in patients with essential hypertension.

Conditions

Interventions

DRUG

LCZ696

LCZ696

DRUG

Placebo

matching placebo to LCZ696

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • China
  • Japan
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01193101 on ClinicalTrials.gov